Pathology Doctors in Minot, ND Accepting Medicare

4 Pathology doctors found. Showing 1 - 4

Mr. George Mark Repp, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Burdick Expy W, Minot, ND 58701 Phone: 701-857-5214    Fax: 701-857-5021

Badie Alakech, MD Pathology - Blood Banking & Transfusion Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000

Dr. Ellen Sigauke, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000

Mr. Wayne L Jansen, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000

News Archive

Chronic exposure to noise and carbon monoxide in the workplace induces hearing loss

Those findings are the result of a study conducted with over 8,600 workers exposed to both noise and carbon monoxide in the workplace. Among the riskier professions are welders, firefighters, garage mechanics, truckers, forklift operators and miners.

American Academy of Dermatology provides tips to 'practice safe sun' outdoors

An estimated 9,500 people in the United States are diagnosed with skin cancer every day, yet many Americans will put themselves at greater risk for skin cancer over the upcoming holiday weekend.

Adults who use marijuana more likely to develop alcohol use disorder

Adults who use marijuana are five times more likely to develop an alcohol use disorder (AUD) -alcohol abuse or dependence- compared with adults who do not use the drug. And adults who already have an alcohol use disorder and use marijuana are more likely to see the problem persist.

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

Read more Medical News

› Verified 3 days ago